Abstract:Two new series of 4,5-difunctionalized 1-bromobenzyl[1,2,3]triazole ( 2a , 3a , 4a , 5a , and 6a) and 4,5-difunctionalized 1-(2-oxo-2-( p -tolylamino)ethyl-[1,2,3]triazole ( 2b , 3b , 4b , 5b , and 6b) were synthesized using related 1-(azidomethyl)-4-bromobenzene 1a and p -tolylcarbamoyl azide 1b respectively. The substituted [1,2,3]triazolo[4,5-d]pyrimidine-7-one derivatives ( 7a , 7b, 8a, and 8b) were synthesized by the reaction of [1,2,3]triazolo derivatives 2a and 2b with carbon disulfide in the presence of 10% sodium hydroxide/dimethylformamide and/or by the reaction with formic acid respectively. The S -glucoside derivatives ( 9–12) of newly synthesized [1,2,3]triazolo[4,5-d]pyrimidines were also synthesized. By using several spectroscopic methods, including IR, 1 H NMR, 13 C NMR, and elemental analysis, the chemical structures of the novel derivatives were confirmed. The synthetic compounds' cytotoxicity and in vitro anticancer activity were examined vs. human breast carcinoma (MCF-7), human laryngeal carcinoma (HEP-2), and human colorectal carcinoma (HCT-116) cell lines. According to the findings, HEP-2 and HCT-116 cells are more sensitive to the tested compounds than the other cell lines. In the HEP-2 and MCF-7 cell lines, respectively, compounds 5b and 11 showed potential anticancer activity when compared to the effect of the commonly used anticancer medication, doxorubicin. The selectivity of compounds against the cancer cell line was confirmed by testing their cytotoxicity on VERO (African Green Monkey kidney) normal cells. The anticancer activity of those compounds is suggested to be due to nuclear damage generated by a high generation of reactive oxygen species (ROS). In addition, the induction of apoptosis by significantly upregulating the apoptotic genes PAR-4 and BAX while substantially downregulating the anti-apoptotic genes BCL-2 and BCL-xl. Molecular docking research was undertaken to predict the probable binding poses of the most effective drugs in the active site of CDK-2. The more active compounds ( 2a, 3a,b, 4a,b, 5a,b, 6b, 11, and 12 ) have been docked on the CDK-2 enzyme to demonstrate their mode of action as anticancer medicines. The compounds exert many interactions and showed high binding to the CDK-2 receptor. Finally, a hypothetical pharmacophore model was created using the Molecular Operating Environment (MOE) software and five compounds that are structurally similar to the synthesized ones with known anticancer action.

Tridentate bipyrazole compounds with a side-arm as a new class of antitumor agents

Design of New Benzo[h]chromene Derivatives: Antitumor Activities and Structure-Activity Relationships of the 2,3-Positions and Fused Rings at the 2,3-Positions

New 3-[(4-hydroxy-6-methly-2(1h)-pyridinones)-3-yl]-4-substituted-(1h)1,2,4- Triazole-5-Thiones: Efficient Synthesis, X-Ray Crystallographic Analysis, and Antitumor Activity

Targeted synthesis via the structure-activity relationship: Biological evaluation of new 1,2,3-triazoles monoterpene as antitumor agents

Synthesis and Antitumor Effects of a New Class of 1,2,4-Triazole Derivatives

Novel Orthodiphenyl Five-Member N-heteroaromatic Compounds As Potent Anticancer Cell Agents

New 1,3,4-Thiadiazole Derivatives with Anticancer Activity

Synthesis and antitumor activity of 4-cyclohexyl/aryl-5-(pyridin-4-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thiones

Synthesis and biological evaluation of 1, 2, 3-triazole incorporated pyrrole derivatives as anticancer agents

Synthesis and biological evaluation of tetrazole ring incorporated oxazole-pyrimidine derivatives as anticancer agents

Design and synthesis of novel 2-(4-(2-(dimethylamino)ethyl)-4H-1,2,4-triazol-3-yl)pyridines as potential antitumor agents.

New 1,2,3-Triazole-Containing Hybrids as Antitumor Candidates: Design, Click Reaction Synthesis, DFT Calculations, and Molecular Docking Study

Rational design of 1,2,3-triazole hybrid structures as novel anticancer agents: synthesis, biological evaluation and molecular docking studies

Design, synthesis, and antitumor activity of novel compounds based on 1,2,4-triazolophthalazine scaffold: Apoptosis-inductive and PCAF-inhibitory effects

Novel [1,2,3]triazoles, [1,2,3]triazolo[4,5-d]Pyrimidines, and Some of Their Glycoside Derivatives: Synthesis and Molecular Modeling as Potential Apoptotic Antitumor Agents

Design, Synthesis, Structure-Activity Relationships and Mechanism of Action of New Quinoline Derivatives As Potential Antitumor Agents

Design, synthesis, and in vitro and in vivo biological evaluation of triazolopyrimidine hybrids as multitarget directed anticancer agents

Synthesis, computational studies and evaluation of benzisoxazole tethered 1,2,4-triazoles as anticancer and antimicrobial agents

New triazole-based coordination complexes as antitumor agents against triple negative breast cancer MDA-MB-468 cell line

Synthesis and Antifungal, Anti-tumor Studies of the Trisubstitued Triazines Bearing Aminopyrimidine Group

Design and Click Synthesis of Novel 1- Substituted-4-(3,4-Dimethoxyphenyl)-1H-1,2,3-Triazole Hybrids for Anticancer Evaluation and Molecular Docking